Search Results

You are looking at 1 - 10 of 49 items for :

  • "177Lu-DOTATATE" x
  • Refine by Access: All content x
Clear All
Free access

Luohai Chen, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, and Shaunak Navalkissoor

Introduction 177 Lutetium-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-Dotatate) is a peptide receptor radionuclide therapy (PRRT) licensed for treatment in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours (NET

Free access

Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom

for PRRT are Yttrium-90 and Lutetium-177, linked to [DOTA 0 ,Tyr 3 ]octreotide ( 90 Y-DOTATOC) or [DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu-DOTATATE), respectively. The objective response rate in patients with gastroenteropancreatic neuroendocrine tumours

Free access

Satya Das, Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana Cardin, Kristen Ciombor, Laura Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, and Jordan Berlin

patients with NETs, its regulatory approvals occurred much more recently ( Otte et al. 1999 , Valkema et al. 2002 ). Lutetium-177 ( 177 Lu)-DOTATATE was approved by the European Medicines Agency (EMA) in 2017 and the Food and Drug Administration (FDA

Free access

Mintallah Haider, Satya Das, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, and Jonathan Strosberg

renal toxicity with 177 Lu-DOTATATE is negligible when prophylactic amino acids are used, even in patients with a glomerular filtration rate < 50mL/min ( Strosberg et al. 2018 b ). Of note, typical formulations of amino acids used for PRRT contain 25

Free access

G A Kaltsas, D Papadogias, P Makras, and A B Grossman

Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell membrane-specific peptide receptors, such as somatostatin receptors (SSTRs), and of which gastroenteropancreatic (GEP), carcinoid and pancreatic islet cell tumours exhibit the highest expression of SSTRs. Radiolabelled receptor-binding somatostatin analogues (octreotide and lanreotide) act as vehicles to guide radioactivity to tissues expressing SSTRs, and can thus be used for their diagnosis and treatment. After the localization of NETs bearing SSTRs with 111In-octreotide (OctreoScan), a number of radioisotopes with different physical properties have been used for their treatment. The administration of high doses of the Auger electron and γ-emitter 111In-diethylenetriaminepenta-acetic acid (DTPA)0,octreotide in patients with metastatic tumours has been associated with considerable symptomatic improvement but relatively few and short-lived objective tumour responses. The use of another radiolabelled somatostatin analogue coupled with 90Y, a pure β-emitter, 90Y-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)0,Tyr3,octreotide (90Y-DOTATOC, OctreoTher), was associated with 10–30% objective tumour response rates, and appears to be particularly effective in larger tumours. 111In- and 90Y-DOTA-lanreotide has also been used for the treatment of NETs although its therapeutic efficacy is probably inferior to that of octreotide-based radiopharmaceuticals. More recently, treatment with 177Lu-DOTA0,Tyr3octreotate (177Lu-DOTATATE), which has a higher affinity for the SSTR subtype 2, resulted in approximately 30% complete or partial tumour responses; this radiopharmaceutical is particularly effective in smaller tumours. Furthermore, treatment using both 90Y-DOTATOC and 177Lu-DOTA0,Tyr3octreotate seems promising, as the combination of these radiopharmaceuticals could be effective in tumours bearing both small and large lesions. Tumour regression is positively correlated with a high level of uptake on 111In-octreotide scintigraphy, limited tumour mass and good performance status. In general, better responses have been obtained in GEP tumours than other NETs. The side effects of this form of therapy are relatively few and mild, particularly when kidney-protective agents are used. Treatment with radiolabelled somatostatin analogues presents a promising tool for the management of patients with inoperable or disseminated NETs, and particularly GEP tumours.

Free access

David Taïeb, Abhishek Jha, Giorgio Treglia, and Karel Pacak

(ileal in 75% of patients) ( Strosberg et al. 2017 ). The interim analysis was encouraging for 177 Lu-DOTATATE, with an objective response of 18 vs 3% compared to octreotide alone, with median progression-free survival (PFS) not yet reached in 177 Lu-DOTATATE

Free access

Tessa Brabander, Julie Nonnekens, and Johannes Hofland

radionuclide therapy (PRRT) ( Kwekkeboom et al. 2005 ). This was successfully implemented for [ 90 Y]Y-DOTA-[Tyr3]octreotide ( 90 Y-DOTATOC) and [ 177 Lu]Lu-DOTA-[Tyr3]octreotate ( 177 Lu-DOTATATE), with the latter radioligand now registered for therapy of

Free access

Jaap J M Teunissen, Dik J Kwekkeboom, R Valkema, and Eric P Krenning

) , different radiolabelled somatostatin analogues were evaluated for future clinical therapeutic use. Besides [ 111 In-DTPA 0 ]octreotide and 90 Y-DOTATOC, the β-emitting radionuclide 177 Lu coupled to DOTATATE ( 177 Lu-DOTATATE) was used. 177 Lu-DOTATATE

Restricted access

Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, Lucas Huebner, Pamela Kunz, Hagen F Kennecke, Edward M Wolin, Jennifer A Chan, Eileen M O’Reilly, Jeffrey A Meyerhardt, and Alan Venook

patients with advanced gastroenteropancreatic neuroendocrine tumors compared to placebo ( Caplin et al. 2014 ). Treatment with the radiolabeled somatostatin analog 177 Lu-Dotatate is increasingly used for the treatment of gastroenteropancreatic

Open access

Anna Angelousi, Aimee R Hayes, Eleftherios Chatzellis, Gregory A Kaltsas, and Ashley B Grossman

Treatment of Locally Advanced metastatic or Unresectable Rare Endocrine Cancers NCT04106843 177 Lu Dotatate Recruiting 2 Others - GFRα4 CAR T Cells in MTC Patients NCT04877613 Single dose of CART-GFRa4 cells vs fludarabine vs